

HLA-B\*27 – bulk  
101.531-48 – licensed for PCR  
101.531-48u – not licensed for PCR  
Lot No.: **X19**

1

www.olerup.com

## **Olerup SSP™ HLA-B\*27 - bulk**

Product number:	101.532-48 – licensed for PCR 101.532-48u – <u>not</u> licensed for PCR
Lot number:	X19
Expiry date:	2009-June-01
Number of tests:	48
Number of tubes per test:	2
Storage:	dark at -20°C

**This Product Description is only valid for Lot No. X19.**

### **CHANGES COMPARED TO THE PREVIOUS OLERUP SSP™ HLA-B\*27 LOT**

The HLA-B\*27 specificity and interpretation tables has been updated for the HLA-B alleles described since the previous *Olerup SSP™* HLA-B\*27 lot (**Lot No. V37**) was made.

The HLA-B\*27 bulk primer set is unchanged compared to the previous *Olerup SSP™* HLA-B\*27 lot (**Lot No. V37**).

## PRODUCT DESCRIPTION

### HLA-B\*27 SSP typing

#### CONTENT

The primer set contains 5'- and 3'-primers for identifying the HLA-B27 specificity, B\*2701 to B\*2737.

The primer solutions consist of specific primer mixes, i.e. group-specific primers as well as a **control primer pair** matching non-allelic sequences.

Positive and negative control DNAs are included in the kit.

DNA 1; a B\*27-positive DNA as a positive control, **IHW 9067, BTB, B\*270502.**

DNA 2; a B\*73-positive DNA as a negative control, **IHW 9280, LK707, B\*520101,7301.** (A B\*7301-positive DNA was chosen as negative control, as this is most similar to the B\*27 group of alleles in the primer matching regions.)

**PCR Master Mix complete with Taq**, Taq polymerase, nucleotides, buffer, glycerol and cresol red, is included in the licensed kit.

**PCR Master Mix without Taq**, nucleotides, buffer, glycerol and cresol red, is included in the unlicensed kit.

2 PCR reactions with a reaction volume of 10 µl is performed per sample.

#### INTERPRETATION

In addition to the HLA-B\*27 alleles, the B\*3702, B\*4704 and B\*4705 will be amplified by primer mix 2 of the HLA-B\*27 kit.

#### UNIQUELY IDENTIFIED ALLELES

All the B\*27 alleles, i.e. **B\*2701 to B\*2737**, recognized by the HLA Nomenclature Committee in April 2007<sup>1</sup> are identified by the primers in the HLA-B\*27 SSP kit.

In addition, the B\*3702, B\*4704 and B\*4705 alleles are amplified by primer mix 2 of the HLA-B\*27 kit.

<sup>1</sup>**Nomenclature for factors of the HLA system, 1998.** *Tissue Antigens* 1999; **53**: 407-446.

HLA-B alleles listed on the IMGT/HLA web page 2007-April-12, release 2.17.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

## LICENSES

### **101.532-48 – licensed for PCR.**

#### **Notice to purchaser: Limited License.**

The purchase price of this product includes limited, non-transferable rights under U.S. Patents 4,683,202, 4,683,195 and 4,965,188 and their foreign counterparts, owned by Roche Molecular Systems, Inc. and F. Hoffman-La Roche Ltd (“Roche”), to use only this amount of the product to practice the Polymerase Chain Reaction (“PCR”) Process described in said patents solely for the HLA Typing applications of the purchaser solely for organ or tissue or bone marrow transplantation, and explicitly excludes analysis of forensic evidence or parentage determination. The rights to use this product to perform and to offer commercial service for HLA Typing for organ or tissue transplantation using PCR, including reporting the results of the purchaser’s activities for a fee or other commercial consideration, is also hereby granted. Further information on purchasing licenses to practice PCR may be obtained by contacting in the United States, the Director of Licensing at Roche Molecular Systems, inc., 1145 Atlantic Avenue, Alameda, California 94501, and outside the United States, the PCR Licensing Manager, F. Hoffmann-La Roche Ltd, Grenzacherstr. 124, CH-4070 Basel, Switzerland.

### **101.532-48u – not licensed for PCR.**

#### **Notice to purchaser: Disclaimer of License.**

This product is optimized for use in the Polymerase Chain Reaction (“PCR”) Process which is covered by patents owned by Roche Molecular Systems, Inc. and F. Hoffmann-La Roche Ltd (“Roche”). No license under these patents to use the PCR Process is conveyed expressly or by implication to the purchaser of this product. Further information on purchasing licenses to practice PCR may be obtained by contacting in the United States, the Director of Licensing at Roche Molecular Systems, inc., 1145 Atlantic Avenue, Alameda, California 94501.

### **101.532-48 and 101.532-48u**

These products use ARMS™ technology and is sold under license from Zeneca Limited. ARMS is the subject of European Patent No. 0332435, US Patent No. 5595890 and corresponding world-wide patents. ARMS is a trademark of Zeneca Limited.

## GUARANTEE

Olerup SSP AB guarantees that the primers in the HLA-B\*27 bulk SSP kit have specificities given in the Specificity and Interpretation Tables of the product insert and in the GenoVision version of the HELMBERG-SCORE™ software.

When stored at -20°C, the primer solutions are stable for 24 months from the date of manufacture.

When stored at -20°C, the PCR Master Mix complete with *Taq* is stable for 24 months from the date of manufacture.

## PROTOCOL

### DNA EXTRACTION

Extracted, highly pure DNA is needed for SSP typings. We recommend isolation of DNA using GenoPrep B200 or GenoPrep B350 cartridges on the GenoM™-6 robotic workstation (GenoVision Europe Tel: +43 1 710 15 00 or GenoVision Inc. USA Tel: +1 610 430 88 41; <http://www.genovision.com>). Using GenoM™-6-extracted DNA ACD, EDTA and heparinised blood can be used as starting material. Because of its high purity, GenoM™-6-extracted DNA can be diluted when used in combination with *Olerup* SSP™ products. The recommended DNA concentration is 15 ng/μl.

Alternatively – BUT DO NOT USE HEPARINISED BLOOD WITH THESE METHODS - the DNA can be extracted using trimethylammoniumbromide salts (DTAB/CTAB) or by salting out. Dissolve the extracted DNA in dH<sub>2</sub>O.

#### IMPORTANT:

Optimal DNA concentration using: GenoM™-6-extracted DNA, 15 ng/μl.

DNA extracted by other methods, 30 ng/μl.

Concentration exceeding 50 ng/μl will increase the risk for nonspecific amplifications and weak extra bands, especially for HLA Class I high resolution SSP typings.

### PCR AMPLIFICATION

#### **101.532-48 – licensed for PCR**

For one HLA-B\*27 bulk typing, dispense 5 μl of each of the 2 HLA-B\*27 bulk primer solutions into an 8 tube strip of 0.2 ml PCR tubes; primer solution 1 into well 1, primer solution 2 into well 2.

For one HLA-B\*27 typing, add at room temperature in a 0.5 ml tube:

4 x 2 μl = 8 μl DNA (30 ng/μl)

4 x 3 μl = 12 μl PCR Master Mix complete with *Taq* – mix well before taking your aliquot

Mix well, dispense 5 μl of the DNA-PCR Master Mix mixture into each of the 2 wells of an HLA-B\*27 typing. Close the 8 tube PCR strip with an 8 strip lid.

#### **101.532-48u – not licensed for PCR**

For one HLA-B\*27 bulk typing, dispense 5 μl of each of the 2 HLA-B\*27 bulk primer solutions into an 8 tube strip of 0.2 ml PCR tubes; primer solution 1 into well 1, primer solution 2 into well 2.

For one HLA-B\*27 typing, add at room temperature in a 0.5 ml tube:

4 x 2 μl = 8 μl DNA (30 ng/μl)

4 x 3 μl = 12 – 0.3 = 11.7 μl PCR Master Mix complete with *Taq* – mix well before taking your aliquot

0.3 μl *Taq* polymerase (5 units/μl)

Mix well, dispense 5 μl of the DNA-PCR Master Mix mixture into each of the 2 wells of an HLA-B\*27 typing. Close the 8 tube PCR strip with an 8 strip lid.

Lot No.: **X19**

www.olerup.com

Use a 96 well thermal cycler with a heated lid. The temperature gradient across the heating block should be < 1°C.

**PCR cycling parameters:**

1. 1 cycle	94°C	2 min	denaturation
2. 10 cycles	94°C	10 sec.	denaturation
	65°C	60 sec.	annealing and extension
3. 20 cycles	94°C	10 sec.	denaturation
	61°C	50 sec.	annealing
	72°C	30 sec.	extension

**The same PCR cycling parameters are used for all the *Olerup* SSP kits.**

**AGAROSE GEL ELECTROPHORESIS**

Prepare a 2% (w/v) agarose gel in 0.5 x TBE buffer. Dissolve the agarose by boiling in a microwave oven. Let the gel solution cool to 60°C. Stain the gel prior to casting with ethidium bromide (10 mg/ml), 5 µl per 100 ml gel solution. For maximal ease of handling use our ethidium bromide dropper bottles (Product No. 103.301-10), 1 drop of ethidium bromide solution per 50-75 ml of gel. **Note:** Ethidium bromide is a powerful carcinogen.

Load the PCR products, preferably using an 8-channel pipette. Load a DNA size marker (100 base pair ladder, Product No. 103.201-100) in one well per row.

Run the gel in 0.5 x TBE buffer, without re-circulation of the buffer, for 15-20 minutes at 8-10 V/cm.

**DOCUMENTATION AND INTERPRETATION**

Put the gel on a UV transilluminator and document by photography.

Record the presence and absence of specific PCR products. The length of the specific PCR product is helpful in the interpretation of the results.

Record the presence of the internal positive control bands.

Lanes without either control band or specific PCR products should be repeated.

Interpret the typings with the ***lot-specific Interpretation and Specificity Tables***.

## PCR MASTER MIXES

The PCR Master Mix complete with *Taq* contains:

<i>Taq</i> polymerase	0.4 unit per 10 $\mu$ l SSP reaction
nucleotides	final concentration of each dNTP is 200 $\mu$ M
PCR buffer	final concentrations: 50 mM KCl, 1.5 mM MgCl <sub>2</sub> , 10 mM Tris-HCl pH 8.3, 0.001% w/v gelatin
glycerol	final concentration of glycerol is 5%
cresol red	final concentration of cresol red is 100 $\mu$ g/ml

**The same PCR Master Mix complete with *Taq* is used for all the licensed *Olerup* SSP kits.**

The PCR Master Mix without *Taq* contains:

nucleotides	final concentration of each dNTP is 200 $\mu$ M
PCR buffer	final concentrations: 50 mM KCl, 1.5 mM MgCl <sub>2</sub> , 10 mM Tris-HCl pH 8.3, 0.001% w/v gelatin
glycerol	final concentration of glycerol is 5%
cresol red	final concentration of cresol red is 100 $\mu$ g/ml

**The same PCR Master Mix without *Taq* is used for all the unlicensed *Olerup* SSP kits.**

The PCR Master Mix complete with *Taq* and the PCR Master Mix without *Taq* can be shipped at ambient temperature.

When stored at  $-20^{\circ}\text{C}$ , the PCR Master Mix complete with *Taq* and the PCR Master Mix without *Taq* are stable for 24 months from the date of manufacture.

Vials with the PCR Master Mixes can be kept at  $+4^{\circ}\text{C}$  for 4 weeks, but the PCR Master Mixes are then no longer stable for 24 months.

## SPECIFICITY TABLE

### HLA-B\*27 SSP typing

Specificity and size of the PCR product of the two primer mixes used for HLA-B\*27 SSP typing.

Primer Mix	Approx. size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA-B*27 alleles	Other amplified HLA-B alleles <sup>3</sup>
1	145 bp	430 bp	2701-270402, 270502-270508, 270510, 2706-2711, 2713-2715, 2717, 2719-2721, 2724, 2725, 2727, 2728, 2730, 2732-2737	
2 <sup>4</sup>	95 bp	515 bp	2701-270402, 270502-270510, 2708, 2710, 2712, 2713, 2715-2718, 2723, 2725, 2726, 2728, 2729, 2731, 2736, 2737	3702, 4704, 4705

<sup>1</sup>Alleles are assigned by the presence of specific PCR product.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen.

PCR fragments longer than the control band may sometimes be observed. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 430 base pairs or a band of 515 base pairs.

Tube number 1 contains the primer pair giving rise to the shorter, 430 bp, internal positive control band in order to help in the correct orientation of the HLA-B\*27 typing.

In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>Due to the sharing of sequence motifs between HLA-B alleles three non-HLA-B\*27 alleles will be amplified by primer mix 2.

<sup>4</sup>Short specific PCR fragments are less intense and not as sharp as longer specific bands.

<b>INTERPRETATION TABLE</b>			
<b>HLA-B*27 SSP typing</b>			
<b>Amplification pattern of the B*2701 to 2737 alleles<sup>1</sup></b>			
	<b>Tube</b>		
	<b>1</b>	<b>2</b>	
<b>Length of spec.</b>	<b>145</b>	<b>95</b>	<b>Length of spec.</b>
<b>PCR product</b>			<b>PCR product</b>
<b>Length of int.</b>	<b>430</b>	<b>515</b>	<b>Length of int.</b>
<b>pos. control<sup>2</sup></b>			<b>pos. control</b>
<b>5'-primer<sup>3</sup></b>	<b>167</b>	<b>363</b>	<b>5'-primer<sup>3</sup></b>
	<sup>5</sup> -gCT <sup>3</sup>	<sup>5</sup> -AAT <sup>3</sup>	
<b>3'-primer<sup>4</sup></b>	<b>272</b>	<b>418</b>	<b>3'-primer<sup>4</sup></b>
	<sup>5</sup> -TgC <sup>3</sup>	<sup>5</sup> -gTC <sup>3</sup>	
<b>Tube No.</b>	<b>1</b>	<b>2</b>	<b>Tube No.</b>
<b>HLA-B allele<sup>5</sup></b>			<b>HLA-B allele<sup>5</sup></b>
<b>*2701-270402, 270502-270508, 270510, 2708, 2710, 2713, 2715, 2717, 2725, 2728, 2736, 2737</b>	<b>+</b>	<b>+</b>	<b>*2701-270402, 270502-270508, 270510, 2708, 2710, 2713, 2715, 2717, 2725, 2728, 2736, 2737</b>
<b>*2706, 2707, 2709, 2711, 2714, 2719-2721, 2724, 2727, 2730, 2732-2735</b>	<b>+</b>		<b>*2706, 2707, 2709, 2711, 2714, 2719-2721, 2724, 2727, 2730, 2732-2735</b>
<b>*270509, 2712, 2716, 2718, 2723, 2726, 2729, 2731, 3702, 4704, 4705</b>		<b>+</b>	<b>*270509, 2712, 2716, 2718, 2723, 2726, 2729, 2731, 3702, 4704, 4705</b>
<b>HLA-B allele<sup>5</sup></b>			<b>HLA-B allele<sup>5</sup></b>
<b>Tube No.</b>	<b>1</b>	<b>2</b>	<b>Tube No.</b>

<sup>1</sup>Due to the sharing of sequence motifs between HLA-B alleles three non-HLA-B\*27 alleles will be amplified by primer mix 2; B\*3702, B\*4704, B\*4705.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 430 base pairs or a band of 515 base pairs.

Tube number 1 contains the primer pair giving rise to the shorter, 430 bp, internal positive control band in order to help in the correct orientation of the HLA-B\*27 typing.

In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>The nucleotide position, in the 2<sup>nd</sup> and 3<sup>rd</sup> exons, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as in *Tissue Antigens* 1998, **51:II**, 417-466. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>4</sup>The nucleotide position, in the 2<sup>nd</sup> and 3<sup>rd</sup> exons, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as in *Tissue Antigens* 1998, **51:II**, 417-466. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>5</sup>The sequence of the B\*270501 allele has been shown to be identical to B\*270502.

The B\*2722 sequence shown to be identical to the corrected B\*2706 sequence.



HLA-B\*27 – bulk  
 101.531-48 – licensed for PCR  
 101.531-48u – not licensed for PCR  
 Lot No.: **X19**

CELL LINE VALIDATION SHEET					
HLA-B*27 unit dose SSP kit					
				Tube	
				1	2
			Production No.	200628301	200628302
	cell line		HLA-B		
1	9001	SA	*0702		- -
2	9280	LK707	*5201	*7301	- -
3	9011	E4181324	*52011		- -
4	9275	GU373	*1510	*5301	- -
5	9009	KAS011	*3701		- -
6	9353	SM	*3901	*5101	- -
7	9020	QBL	*1801		- -
8	9007	DEM	*5701		- -
9	9026	YAR	*3801		- -
10	9107	LKT3	*5401		- -
11	9051	PITOUT	*4403		- -
12	9052	DBB	*5701		- -
13	9067	BTB	*2705		+ +
14	9071	OLGA	*1501	*1520	- -
15	9075	DKB	*4001		- -
16	9037	SWEIG007	*4002		- -
17	9008	WILJON	*1801		- -
18	9257	32367	*1401	*5601	- -
19	9038	BM16	*1801		- -
20	9059	SLE005	*4001		- -
21	9064	AMALA	*1501		- -
22	9056	KOSE	*3503		- -
23	9124	IHL	*4002	*5602	- -
24	9035	JBUSH	*3801		- -
25	9049	IBW9	*1402		- -
26	9285	WT49	*5801		- -
27	9191	CH1007	*0705	*5101	- -
28	9320	BEL5GB	*4402	*4403	- -
29	9050	MOU	*4403		- -
30	9021	RSH	*4201		- -
31	9019	DUCAF	*1801		- -
32	9297	HAG	*4102		- -
33	9098	MT14B	*4001		- -
34	9104	DHIF	*3801		- -
35	9302	SSTO	*4402		- -
36	9024	KT17	*1501	*3501	- -
37	9065	HHKB	*0702		- -
38	9099	LZL	*1501		- -
39	9315	CML	*0801	*2705	+ +
40	9134	WHONP199	*1302	*4601	- -
41	9055	H0301	*1402		- -
42	9066	TAB089	*4601		- -
43	9076	T7526	*4601		- -
44	9057	TEM	*3801		- -
45	9239	SHJO	*4201	*5001	- -
46	9013	SCHU	*0702		- -
47	9045	TUBO	*5101		- -
48	9303	TER-ND	*3501	*4403	- -

HLA-B\*27 – bulk  
101.531-48 – licensed for PCR  
101.531-48u – not licensed for PCR  
Lot No.: X19

10

www.olerup.com

## CERTIFICATE OF ANALYSIS

### **Olerup SSP™ HLA-B\*27 SSP**

Product number: 101.532-48 – licensed for PCR  
101.532-48u – not licensed for PCR  
Lot number: X19  
Expiry date: 2009-June-01  
Number of tests: 48  
Number of tubes per test: 2

#### **Tube specifications:**

Tube No.	Production No.
1	2006-283-01
2	2006-283-02

The specificity of the primer solutions of the kit has been tested against 48 well characterized cell line DNAs.

**Results:** No false positive or false negative amplifications were obtained.

**Date of approval:** 2007-June-14

**Approved by:**

**Quality Control, Supervisor**

## Declaration of Conformity

**Product name:** Olerup SSP™ HLA-B\*27 bulk  
**Product number:** 101.532-48/101.532-48U  
**Lot number:** X19

**Intended use:** HLA-B\*27 low resolution histocompatibility testing

**Manufacturer:** Olerup SSP AB  
Hasselstigen 1  
SE-133 33 Saltsjöbaden, Sweden  
**Phone:** +46-8-717 88 27  
**Fax:** +46-8-717 88 18

We, Olerup SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2000 and ISO 13485:2003, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex II List B, conformity assessed using Annex IV, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at Olerup SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

The Authorized Representative located within the Community is: Olerup SSP AB.

Notified Body: Lloyd's Register Quality Assurance Limited, Hiramford, Middlemarch Office Village, Siskin Drive, Coventry CV3 4FJ, United Kingdom. (Notified Body number: 0088.)

Saltsjöbaden, Sweden  
2007-June-14

Olle Olerup  
Managing Director

HLA-B\*27 – bulk  
101.531-48 – licensed for PCR  
101.531-48u – not licensed for PCR  
Lot No.: **X19**

12

[www.olerup.com](http://www.olerup.com)

HLA-B\*27 – bulk  
101.531-48 – licensed for PCR  
101.531-48u – not licensed for PCR  
Lot No.: **X19**

13

[www.olerup.com](http://www.olerup.com)

HLA-B\*27 – bulk  
101.531-48 – licensed for PCR  
101.531-48u – not licensed for PCR  
Lot No.: **X19**

14

[www.olerup.com](http://www.olerup.com)

## WARRANTY

*Olerup* SSP AB warrants its products to the original purchaser against defects in materials and workmanship under normal use and application. *Olerup* SSP AB's sole obligation under this warranty shall be to replace, at no charge, any product that does not meet the performance standards stated on the product specification sheet.

This warranty applies only to products that have been handled and stored in accordance with *Olerup* SSP AB's recommendations, and does not apply to products that have been the subject of alternation, misuse, or abuse.

All claims under this warranty must be directed to *Olerup* SSP AB in writing and must be accompanied by a copy of the purchaser's invoice. This warranty is in lieu of all other warranties, expressed or implied, including the warranties of merchantability and fitness for a particular purpose. In no case shall *Olerup* SSP AB be liable for incidental or consequential damages.

This product may not be reformulated, repacked or resold in any form without the written consent of *Olerup* SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

Handle all samples as if capable of transmitting disease. All work should be performed wearing gloves and appropriate protection.

*Olerup* SSP™ is a trademark of *Olerup* SSP AB.  
PCR™ is a trademark of F. Hoffmann-La Roche Ltd.  
ARMS™ is a trademark of Zeneca Ltd.

HLA-B\*27 – bulk  
101.531-48 – licensed for PCR  
101.531-48u – not licensed for PCR  
Lot No.: **X19**

16

[www.olerup.com](http://www.olerup.com)

**ADDRESSES:**

**Manufacturer:**

**Olerup SSP AB**, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

**Tel:** +46-8-717 88 27

**Fax:** +46-8-717 88 18

**E-mail:** [info-ssp@olerup.com](mailto:info-ssp@olerup.com)

**Web page:** <http://www.olerup.com>

**Distributed by:**

**Olerup GmbH**, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

**Tel:** +43-1-710 15 00

**Fax:** +43-1-710 15 00 10

**E-mail:** [support-at@olerup.com](mailto:support-at@olerup.com)

**Web page:** <http://www.olerup.com>

**Olerup Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-OLERUP1

**Fax:** 610-344-7989

**E-mail:** [info.us@olerup.com](mailto:info.us@olerup.com)

**Web page:** <http://www.olerup.com>

For information on *Olerup* SSP distributors worldwide, contact **Olerup GmbH**.